Blockchain Registration Transaction Record

Synbio International Modernizes Trading with DWAC/DRS Approval

Synbio International achieves DWAC and DRS approval for electronic trading, reducing settlement times and improving investor accessibility for its AI medical diagnostics platform.

This development matters because it directly impacts investor experience and market efficiency for Synbio International shareholders. By implementing DWAC and DRS systems, the company reduces settlement times from days to potentially hours, lowers transaction costs, and eliminates the risks associated with physical certificate handling. For retail investors, this means faster access to funds when selling shares and simpler portfolio management. For the company, it enhances liquidity and market accessibility, which can attract institutional investors and support capital raising efforts. In the broader context of OTC markets, such infrastructure improvements signal maturation and increased investor protection, potentially leading to better valuation and reduced volatility. As Synbio advances its AI-driven medical diagnostics platform, efficient trading infrastructure becomes crucial for executing strategic partnerships and financing activities that could accelerate development of healthcare technologies affecting patient outcomes.